Olympus, Boston Scientific & more — 3 GI company key notes

Here are three updates on gastroenterology and endoscopy companies.

Advertisement

Paris, France-based Nanobiotix reported the results of its phase I/II clinical trial for NBTXR3, its liver cancer drug.

Three senior Olympus executives utilized their right to invoke the Fifth Amendment during questioning over internal company emails.

Following news about superbug outbreaks at numerous facilities, providers and hospitals are trying out disposable scopes, such as Boston Scientific’s single-use bronchoscope.

More articles on gastroenterology and endoscopy:
Which lifestyle factors are associated with serrated colorectal polyps? 5 study insights
AGA critiques ABIM maintenance of certification announcement: 3 takeaways
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis

Advertisement

Next Up in GI & Endoscopy

  • Below is a list of five gastroenterology leaders in the U.S. who have made a positive impact on their organizations…

  • Chicago-based GI Partners of Illinois saw its GI case mix tilt toward more complex, chronic and multidisciplinary care in 2025,…

Advertisement

Comments are closed.